Date: 2017-07-19
Type of information: Nomination
Compound: member of the scientific advisory board
Company: Sagetis Biotech (Spain)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 19, 2017, Sagetis Biotech announced that it has expanded its Scientific Advisory Board (SAB) with the appointment of Dr. Manuel Hidalgo. Dr. Hidalgo is an internationally renowned oncologist in the treatment of pancreatic cancer. Currently, he serves as Clinical Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center in Boston where he is also Co-Director of the Pancreatic Cancer Research Program. Dr. Hidalgo is also Professor of Medicine at the Harvard Medical School. His ground-breaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer. This encompasses the early clinical development of more than 50 new anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer.
- His most significant contribution has been the pioneering of patient derived xenograft models for drug screening, biomarker development and personalized medicine in Pancreatic Ductal Adenocarcinoma (PDAC). About 15 years ago he initiated the development of patient derived xenograft models of pancreas cancer as a platform for translational studies in this disease. Dr. Hidalgo has been the recipient of a European Research Council advanced grant.
- Dr. Manuel Hidalgo will join existing members of Sagetis SAB: Dr. Cristina Fillat, Gene Therapy and Cancer Principal Investigator at IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Dr. Ramon Alemany, Head researcher at the gene and viral cancer therapy at Institut Català d’Oncologia (ICO)-Idibell and an internationally recognized expert in oncolytic adenoviruses for cancer treatment, Prof. Salvador Borrós, Co-founder, member of the Board at Sagetis Biotech and Full Professor at IQS and Dr. Robert Elfont, John-Hopkins-trained neurologist with subspecialty training in neuroimmunology and neurovirology.
Financial terms:
Latest news:
Is general: Yes
